SecBot SecBot
SECBOTREPLAY Home › Report › TRDA

TRDA · Entrada Therapeutics filed an 8-K reporting the results of its 2026…

Entrada Therapeutics, Inc. · 8-K filed Jun 10, 2026 at 16:06 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Jun 10, 2026 at 16:06 ET

Entrada Therapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Stockholders approved amendments to the company's 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan to include pre-funded warrants in the evergreen share calculation. Two Class II directors were elected and Ernst & Young was ratified as auditor. This is a routine governance filing with no material financial impact.

  • Stockholders approved Amendment No. 1 to the 2021 Stock Option and Incentive Plan and the 2021 Employee Stock Purchase Plan, adding pre-funded warrants to the evergreen formula's outstanding share count.
  • Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. were elected as Class II directors.
  • Ernst & Young LLP was ratified as independent auditor for fiscal year 2026.
  • 38,820,616 shares outstanding as of record date April 13, 2026; 33,190,234 shares present at meeting.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access